Skip to content
DraconiticResearch
Search Sources API
181,713 studies31 sourcesUpdated 37 min ago
Peer-reviewedCC BYMuscles (Basel, Switzerland)

Melatonin and Cisplatin-Associated Skeletal Muscle Wasting and Atrophy: Mechanistic Rationale, Current Evidence, and Research Gaps.

  • Mohamed A A Hassan1
  • Mahmoud Abd-Elnaeim2
  • Enas A Abd-Elhafez3
  • Ramy K A Sayed1
  1. 1Department of Anatomy and Embryology, Faculty of Veterinary Medicine, Sohag University, Sohag 82524, Egypt.
  2. 2Department of Anatomy and Embryology, Faculty of Veterinary Medicine, Assiut University, Assiut 71526, Egypt.
  3. 3Department of Cell and Tissues, Faculty of Veterinary Medicine, Assiut University, Assiut 71526, Egypt.
Read full textPDFDOICite

Abstract

Cisplatin causes skeletal muscle wasting in tumor-free rodents, reducing muscle mass, myofiber size and, where measured, strength. This critical narrative review appraises that phenotype and its mechanistic basis. Tumor-bearing models show that the loss also occurs under tumor burden, but most cannot separate drug from tumor effects. Melatonin influences mitochondrial, redox, regenerative, and structural outcomes in skeletal muscle under non-cisplatin conditions. Direct melatonin-cisplatin evidence is limited to pretreatment studies in C2C12 cells from one research group. No in vivo melatonin-plus-cisplatin skeletal-muscle study and no clinical study of melatonin against cisplatin-associated muscle loss were identified in searches through 22 September 2026. Biological plausibility is supported, but protection has not been demonstrated. A controlled tumor-free study would provide a more interpretable test of whether melatonin protects skeletal muscle during cisplatin exposure. Translational validation would then require a separate tumor-bearing study testing whether protection persists under tumor burden and whether cisplatin's antitumor activity is preserved.

Related

  1. AMPK-Directed Therapeutics for MASLD: Mechanistic Rationale, Activator Classes, and Clinical Translation
    Reeju Amatya, Ji Yeon Hyun, Jun Hak Lee +2
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0Molecular biology & gene regulationCrossref
  2. Circular RNAs in Skeletal Muscle Aging and Sarcopenia: Mechanistic Evidence, Biomarker Potential, and Therapeutic Readiness
    Thanh Huu Phan Ngo, Wan Lee
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0Full textMolecular biology & gene regulationCrossrefEurope PMC
  3. Integrated toxicogenomic and single-nucleus transcriptomic analyses prioritize SDHB and NDUFAB1 in mitochondrial respiration-associated remodeling during cisplatin-induced acute kidney injury
    Dianjie Zeng, Yunhui He, Huijie Hu +2
    Frontiers in cell and developmental biologyPeer-reviewedCC BYFull textGeneral biochemistryEurope PMC
  4. A Batch-Aware, Subject-Grouped Pipeline to Prioritize HIIT-Associated DNA Methylation Candidates with Cross-Cohort Evaluation in Skeletal Muscle
    Bruce Mingyeung Song, Kenneth Hon Kim Ban, Caroline Guat Lay Lee +1
    International journal of molecular sciencesPeer-reviewedCC BYFull textGeneral biochemistryEurope PMC
  5. Stage-specific transcriptional atlas of goose satellite cells uncovers sex-biased molecular dynamics associated with embryonic skeletal muscle development
    Cui Wang, Kai Shi, Yi Liu +6
    Frontiers in cell and developmental biologyPeer-reviewedCC BYFull textGeneral biochemistryEurope PMC

Cite

BibTeXRIS
BibTeX
@article{hassan2026melatonin,
  title = {{Melatonin and Cisplatin-Associated Skeletal Muscle Wasting and Atrophy: Mechanistic Rationale, Current Evidence, and Research Gaps.}},
  author = {Mohamed A A Hassan and Mahmoud Abd-Elnaeim and Enas A Abd-Elhafez and Ramy K A Sayed},
  journal = {Muscles (Basel, Switzerland)},
  year = {2026},
  month = oct,
  doi = {10.3390/muscles5040076},
  url = {https://europepmc.org/article/MED/42924648},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Melatonin and Cisplatin-Associated Skeletal Muscle Wasting and Atrophy: Mechanistic Rationale, Current Evidence, and Research Gaps.
AU  - Mohamed A A Hassan
AU  - Mahmoud Abd-Elnaeim
AU  - Enas A Abd-Elhafez
AU  - Ramy K A Sayed
PY  - 2026
DA  - 2026/10/16
JO  - Muscles (Basel, Switzerland)
DO  - 10.3390/muscles5040076
UR  - https://europepmc.org/article/MED/42924648
AB  - Cisplatin causes skeletal muscle wasting in tumor-free rodents, reducing muscle mass, myofiber size and, where measured, strength. This critical narrative review appraises that phenotype and its mechanistic basis. Tumor-bearing models show that the loss also occurs under tumor burden, but most cannot separate drug from tumor effects. Melatonin influences mitochondrial, redox, regenerative, and structural outcomes in skeletal muscle under non-cisplatin conditions. Direct melatonin-cisplatin evidence is limited to pretreatment studies in C2C12 cells from one research group. No in vivo melatonin-plus-cisplatin skeletal-muscle study and no clinical study of melatonin against cisplatin-associated muscle loss were identified in searches through 22 September 2026. Biological plausibility is supported, but protection has not been demonstrated. A controlled tumor-free study would provide a more interpretable test of whether melatonin protects skeletal muscle during cisplatin exposure. Translational validation would then require a separate tumor-bearing study testing whether protection persists under tumor burden and whether cisplatin's antitumor activity is preserved.
SN  - 2813-0413
ER  -